ホーム › 頭頸部扁平上皮癌 › マサチューセッツ州 › Boston
Boston、MAにおける頭頸部扁平上皮癌の臨床試験
Bostonとその周辺地域（約30マイル以内）の拠点で、頭頸部扁平上皮癌に関する40件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital, Boston
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
被験者募集中第2/3相
- Site #0131, Boston
- Site#0101, Boston
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #7, Boston
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
被験者募集中第3相
- Boston Medical Center, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
被験者募集中第1相
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
被験者募集中第1相
- Research Site, Boston
- Research Site, Boston
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
被験者募集中第3相
- Dana Farber Cancer Institute, Boston
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
被験者募集中第3相
- Boston Medical Center, Boston
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
被験者募集中第1相
- Boston Medical Center, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
被験者募集中第1/2相
- Tufts Medical Center, Boston
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
被験者募集中第2相
- Tufts Medical Center, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
被験者募集中第2相
- Tufts Medical Center, Boston
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
被験者募集中第1相
- Massachusetts General Hospital, Boston
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
被験者募集中観察研究
- Dana Farber Cancer Institute, Boston
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
被験者募集中第2相
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
被験者募集中第1相
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
被験者募集中第2相
- Boston Medical Center, Boston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital - Dana Farber, Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
被験者募集中第1相
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
PDT For Induction Therapy For Head And Neck Cancer
被験者募集中第2相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- 他2件
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
被験者募集中第2相
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
被験者募集中第1相
- Beth Israel Deaconess Medical Center /ID# 252009, Boston
- Dana-Farber Cancer Institute /ID# 249642, Boston
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
被験者募集中第3相
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
被験者募集中第1/2相
- Dana-Farber Cancer Institute, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
被験者募集中第1相
- Dana Farber Cancer Institute, Boston
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
被験者募集中第2相
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
被験者募集中早期第1相
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
被験者募集中第1相
- Dana Farber/Partners Cancer Care Inc, Boston
Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck
被験者募集中観察研究
- Massachusetts Eye and Ear, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
被験者募集中第2相
- Dana Farber Cancer Institute, Boston
他の都市における頭頸部扁平上皮癌の試験
- Houston, TX47件の研究
- Los Angeles, CA42件の研究
- New York City, NY39件の研究
- Nashville, TN39件の研究
- St. Louis, MO28件の研究
- Arlington, VA26件の研究
- Philadelphia, PA26件の研究
- Chicago, IL26件の研究
- Atlanta, GA24件の研究
- San Antonio, TX22件の研究
- New Haven, CT22件の研究
- Pittsburgh, PA22件の研究
Bostonにおける他の研究
- 乳がん112件の研究
- 非小細胞肺癌90件の研究
- がん（全種類）85件の研究
- 転移性癌63件の研究
- 大腸癌63件の研究
- 肺がん62件の研究
- 卵巣がん61件の研究
- 前立腺がん59件の研究
- うつ病52件の研究
- 子宮内膜がん50件の研究
- 心不全44件の研究
- 急性骨髄性白血病44件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。